KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Acquisitions & Divestments: 2014-2025

Historic Change in Acquisitions & Divestments for Xenon Pharmaceuticals (XENE) over the last 10 years, with Sep 2025 value amounting to $113.5 million.

  • Xenon Pharmaceuticals' Change in Acquisitions & Divestments fell 31.28% to $113.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $616.2 million, marking a year-over-year decrease of 8.25%. This contributed to the annual value of $700.3 million for FY2024, which is 1.77% up from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Change in Acquisitions & Divestments of $113.5 million as of Q3 2025, which was down 33.71% from $171.2 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Change in Acquisitions & Divestments registered a high of $235.7 million during Q2 2024, and its lowest value of $20.3 million during Q1 2022.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $165.6 million (2024), whereas its average is $167.2 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Change in Acquisitions & Divestments tumbled by 55.87% in 2022, and later surged by 674.70% in 2023.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Change in Acquisitions & Divestments stood at $42.3 million in 2021, then soared by 147.80% to $104.8 million in 2022, then spiked by 30.66% to $136.9 million in 2023, then increased by 21.01% to $165.6 million in 2024, then plummeted by 31.28% to $113.5 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $113.5 million for Q3 2025, versus $171.2 million for Q2 2025 and $165.8 million for Q1 2025.